Chen Zhicong, Cao Jinming, Xiao Zhijun, Yang Zhen, Cheng Yuanchi, Duan Jingjing, Zhou Ting, Xu Feng
Fengxian Hospital, School of Pharmaceutical Sciences, Southern Medical University, Shanghai, China.
Sixth People's Hospital South Campus, Shanghai Jiaotong University, Shanghai, China.
Front Pharmacol. 2024 Dec 10;15:1485885. doi: 10.3389/fphar.2024.1485885. eCollection 2024.
This study aimed to investigate the underlying mechanism of chronic stress promoting ovarian cancer growth comorbid with depression and evaluate the potential role of histamine (HIS) in treating this comorbidity.
Chronic unpredictable mild stress (CUMS) was used to establish a comorbid mouse model of ovarian cancer and depression. The behavioral phenotypes were assessed using the sucrose preference test (SPT), tail suspension test (TST), forced swimming test (FST), and open field test (OFT). Ovarian cancer growth was monitored by tracking the tumor volume and weight. Histidine decarboxylase (HDC) expression in the tumor tissue was analyzed using Western blot and qRT-PCR techniques. The serum levels of inflammatory factors (IL-6 and IL-17A), stress hormones (norepinephrine, NE and cortisol, and COR), histamine, and 5-hydroxytryptamine (5-HT) were detected by enzyme-linked immunosorbent assay (ELISA). experiments were conducted to explore the direct impacts of stress hormones on A2780 and ES-2 ovarian cancer cell lines, as well as the modulation of these effects by histamine. HDC knockdown and overexpression approaches were used to study its regulatory role in the IL-6/STAT3/S100A9 signaling pathway.
Chronic stress not only induced depressive behaviors but also accelerated ovarian cancer growth in mice by downregulating HDC expression in tumors, whereas exogenous HIS treatment alleviated depressive symptoms, suppressed cancer growth, and countered the decreased levels of HIS and increased levels of IL-6, IL-17A, NE, COR, and 5-HT induced by CUMS. Furthermore, HIS positively modulated the immune response by increasing the populations of CD3T and CD8 T cells and reducing IL-17A secretion. experiments revealed that stress hormones downregulated HDC expression, consequently promoting cancer cell proliferation, migration, and invasion via the IL-6/STAT3/S100A9 pathway. Knockdown of HDC activated this pathway, whereas HDC overexpression inhibited its activation.
Chronic stress leads to the downregulation of HDC expression, thereby facilitating the progression of ovarian cancer through the IL-6/STAT3/S100A9 pathway. HIS might serve as a potential molecule for treating the comorbidities of ovarian cancer and depression.
本研究旨在探讨慢性应激促进卵巢癌生长合并抑郁症的潜在机制,并评估组胺(HIS)在治疗这种合并症中的潜在作用。
采用慢性不可预测轻度应激(CUMS)建立卵巢癌和抑郁症合并的小鼠模型。使用蔗糖偏好试验(SPT)、悬尾试验(TST)、强迫游泳试验(FST)和旷场试验(OFT)评估行为表型。通过跟踪肿瘤体积和重量监测卵巢癌生长。使用蛋白质免疫印迹和qRT-PCR技术分析肿瘤组织中组氨酸脱羧酶(HDC)的表达。通过酶联免疫吸附测定(ELISA)检测血清中炎症因子(IL-6和IL-17A)、应激激素(去甲肾上腺素、NE和皮质醇、COR)、组胺和5-羟色胺(5-HT)的水平。进行实验以探索应激激素对A2780和ES-2卵巢癌细胞系的直接影响,以及组胺对这些影响的调节作用。使用HDC敲低和过表达方法研究其在IL-6/STAT3/S100A9信号通路中的调节作用。
慢性应激不仅诱导小鼠出现抑郁行为,还通过下调肿瘤中HDC的表达加速卵巢癌生长,而外源性HIS治疗可缓解抑郁症状、抑制癌症生长,并对抗CUMS诱导的HIS水平降低以及IL-6、IL-17A、NE、COR和5-HT水平升高。此外,HIS通过增加CD3T和CD8 T细胞数量并减少IL-17A分泌来正向调节免疫反应。实验表明,应激激素下调HDC表达,从而通过IL-6/STAT3/S100A9途径促进癌细胞增殖、迁移和侵袭。敲低HDC激活该途径,而过表达HDC则抑制其激活。
慢性应激导致HDC表达下调,从而通过IL-6/STAT3/S100A9途径促进卵巢癌进展。HIS可能是治疗卵巢癌和抑郁症合并症的潜在分子。